We are analyzing https://link.springer.com/article/10.1007/s10147-003-0332-x.

Title:
Target molecules in specific immunotherapy against prostate cancer | International Journal of Clinical Oncology
Description:
Recent advances in molecular biology and tumor immunology have allowed us to identify genes encoding human cancer-related antigens and their peptides that are recognized by cytotoxic T lymphocytes (CTLs). Although these advances have been preceded by studies on melanoma antigens, prostate cancer is another target candidate for specific immunotherapy. Several prostate tissue-specific antigens can be target molecules in specific immunotherapy for prostate cancer. The distribution of prostate tissue-specific antigens is more localized than that of melanoma-related antigens. Prostate-specific antigen (PSA) is available as an evaluation indicator of clinical course. In addition, epithelial cancer-related antigens are also applicable for prostate cancer patients. These lines of evidence suggest that prostate cancer is the best candidate for specific immunotherapy among the various types of epithelial cancers. A number of epitope peptides which have the potential to generate prostate cancer-reactive CTLs have been identified to date, and clinical trials targeting these molecules have been conducted. In this article, we review prostate cancer-related antigens and their epitope peptides, which have potential for use in the immunotherapy of prostate cancer patients, and we introduce the current status of clinical trials of specific immunotherapy targeting these molecules.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

prostate, cancer, article, immunotherapy, antigens, specific, privacy, cookies, content, journal, clinical, target, molecules, publish, search, harada, access, kurume, data, information, log, research, review, mamoru, noguchi, itoh, advances, cancerrelated, peptides, ctls, targeting, discover, author, springer, optional, personal, parties, policy, find, track, international, oncology, cite, masanori, kyogo, explore, recent, molecular, immunology, cytotoxic,

Topics {✒️}

epithelial cancer-related antigens month download article/chapter prostate tissue-specific antigens prostate cancer patients molecular biology melanoma-related antigens privacy choices/manage cookies article international journal peptide vaccine access specific immunotherapy targeting prostate cancer prostate-specific antigen full article pdf related subjects clinical oncology aims author correspondence clinical trials targeting european economic area conditions privacy policy journal finder publish accepting optional cookies mamoru harada kurume university school target molecules article harada target candidate melanoma antigens specific immunotherapy information affiliations department article log privacy policy personal data check access instant access books a recent advances clinical trials journal publish optional cookies manage preferences epithelial cancers itoh article cite subscription content similar content data protection essential cookies cookies skip institution subscribe

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Target molecules in specific immunotherapy against prostate cancer
         description:Recent advances in molecular biology and tumor immunology have allowed us to identify genes encoding human cancer-related antigens and their peptides that are recognized by cytotoxic T lymphocytes (CTLs). Although these advances have been preceded by studies on melanoma antigens, prostate cancer is another target candidate for specific immunotherapy. Several prostate tissue-specific antigens can be target molecules in specific immunotherapy for prostate cancer. The distribution of prostate tissue-specific antigens is more localized than that of melanoma-related antigens. Prostate-specific antigen (PSA) is available as an evaluation indicator of clinical course. In addition, epithelial cancer-related antigens are also applicable for prostate cancer patients. These lines of evidence suggest that prostate cancer is the best candidate for specific immunotherapy among the various types of epithelial cancers. A number of epitope peptides which have the potential to generate prostate cancer-reactive CTLs have been identified to date, and clinical trials targeting these molecules have been conducted. In this article, we review prostate cancer-related antigens and their epitope peptides, which have potential for use in the immunotherapy of prostate cancer patients, and we introduce the current status of clinical trials of specific immunotherapy targeting these molecules.
         datePublished:
         dateModified:
         pageStart:193
         pageEnd:199
         sameAs:https://doi.org/10.1007/s10147-003-0332-x
         keywords:
            Prostate cancer
            Immunotherapy
            Cytotoxic T lymphocytes (CTLs)
            Peptide
            Vaccine
            Oncology
            Surgical Oncology
            Cancer Research
         image:
         isPartOf:
            name:International Journal of Clinical Oncology
            issn:
               1437-7772
               1341-9625
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mamoru Harada
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Masanori Noguchi
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kyogo Itoh
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Target molecules in specific immunotherapy against prostate cancer
      description:Recent advances in molecular biology and tumor immunology have allowed us to identify genes encoding human cancer-related antigens and their peptides that are recognized by cytotoxic T lymphocytes (CTLs). Although these advances have been preceded by studies on melanoma antigens, prostate cancer is another target candidate for specific immunotherapy. Several prostate tissue-specific antigens can be target molecules in specific immunotherapy for prostate cancer. The distribution of prostate tissue-specific antigens is more localized than that of melanoma-related antigens. Prostate-specific antigen (PSA) is available as an evaluation indicator of clinical course. In addition, epithelial cancer-related antigens are also applicable for prostate cancer patients. These lines of evidence suggest that prostate cancer is the best candidate for specific immunotherapy among the various types of epithelial cancers. A number of epitope peptides which have the potential to generate prostate cancer-reactive CTLs have been identified to date, and clinical trials targeting these molecules have been conducted. In this article, we review prostate cancer-related antigens and their epitope peptides, which have potential for use in the immunotherapy of prostate cancer patients, and we introduce the current status of clinical trials of specific immunotherapy targeting these molecules.
      datePublished:
      dateModified:
      pageStart:193
      pageEnd:199
      sameAs:https://doi.org/10.1007/s10147-003-0332-x
      keywords:
         Prostate cancer
         Immunotherapy
         Cytotoxic T lymphocytes (CTLs)
         Peptide
         Vaccine
         Oncology
         Surgical Oncology
         Cancer Research
      image:
      isPartOf:
         name:International Journal of Clinical Oncology
         issn:
            1437-7772
            1341-9625
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mamoru Harada
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Masanori Noguchi
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kyogo Itoh
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Clinical Oncology
      issn:
         1437-7772
         1341-9625
      volumeNumber:8
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mamoru Harada
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Masanori Noguchi
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Kyogo Itoh
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
      name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(28)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.72s.

LINK . SPRINGER . COM {}